XJPX
4531
Market cap51mUSD
Oct 09, Last price
378.00JPY
1D
1.34%
1Q
1.89%
Jan 2017
48.82%
Name
Yuki Gosei Kogyo Co Ltd
Chart & performance
P/E
26.10
P/S
0.53
EPS
14.48
Div yield, %
2.41%
Shrs. gr., 5y
-0.22%
Rev. gr., 5y
6.85%
Revenues
15.45b
+2.12%
Net income
313m
-65.07%
CFO
2.84b
+32.71%
Dividend
Mar 30, 202710 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yuki Gosei Kogyo Co., Ltd. is a Japanese enterprise that globally researches, develops, produces, and markets sophisticated fine chemical products. Their diverse portfolio encompasses food-grade additives, pharmaceutical components, and chemicals for industrial and agricultural applications. Key offerings include glycine and its derivatives, nicotinamide, isoniazid, various drug intermediates, and cosmetic raw materials. The company also provides a range of specialized compounds, such as those based on amino acids, pyridine, piperidine, and silicon, alongside biological products like DNA, nucleosides, protamine, and active pharmaceutical ingredients (APIs). Furthermore, they offer contract manufacturing services for pharmaceutical and chemical products. Established in 1947, Yuki Gosei Kogyo Co., Ltd. is headquartered in Tokyo, Japan.
Key people
Seiichiro Matsumoto
Executive President, Chief Executive Officer, Representative Director · since 2019
Masahiro Kusano
Managing Executive Officer, Director · since 2023
Masao Matsukawa
Senior Executive Officer, Director of 1st Sales, Senior Director of Sales · since 2025
Makoto Kito
Executive Officer, Manager of Tokiwa Plant, Chief Director of Production Administration · since 2025
Hiroshi Nakamura
Executive Officer, Director of Quality Assurance · since 2023
Tetsuji Noda
Executive Officer, Director of Tokyo Research Institute · since 2025
Hiromi Ishikawa
Senior Executive Officer, Director · since 2025
Naotake Suto
Director · since 2020
Norito Ohori
Independent Director · since 2020
Keisuke Yamada
Independent Director · since 2014
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||